PARP inhibitors during conception and pregnancy in breast cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Young women with breast cancer carrying BRCA mutations should avoid PARP inhibitors during pregnancy due to potential harm to fertility and pregnancy. This review offers guidance on their use in women of childbearing potential.
Area Of Science
- Oncology
- Genetics
- Reproductive Medicine
Background
- Germline BRCA pathogenic variants are found in ~10% of women under 35 with breast cancer.
- PARP inhibitors are approved for early and advanced breast cancer treatment.
- No data exists on PARP inhibitor use during pregnancy.
Purpose Of The Study
- To summarize clinical and preclinical data on PARP inhibitors' effects on pregnancy, fertility, and breastfeeding.
- To provide guidance for optimal use in women of childbearing potential.
Main Methods
- Literature review of clinical and preclinical studies.
- Analysis of data on PARP inhibitors, pregnancy, fertility, and breastfeeding.
Main Results
- PARP inhibitors are contraindicated during pregnancy.
- Potential for harm to fertility in young women with breast cancer.
- Limited data on breastfeeding exposure.
Conclusions
- PARP inhibitors pose risks during pregnancy and may affect fertility.
- Further research is needed to establish safe use guidelines for women of childbearing potential.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...